Replies to post #6406 on Celsion Corporation (CLSN)

[Rawnoc]

Nov 28 2011: 613 patients reviewed, 219 progression-free survival events
http://investor.celsion.com/releasedetail.cfm?ReleaseID=627024

Nov 9 2012: 701 patients, 380 progression-free survival events
http://investor.celsion.com/releasedetail.cfm?ReleaseID=720097

July 11 2011: 345 patients with no events
Nov 28 2011: 394 patients with no events
Nov 9 2012: 161 more patients had events

40.8% in the 12.5 month period with hundreds of the patients being in the trial for over 2 years.

60% recurrence rate for RFA+alone + 20% rate for RFA+ThermoDox = 40% average?

In other words Thermodox 200% vs. 33% necessary?

Probably doing something wrong. Hence 80% to 100% which is still a huge home run.

[errett]

Rawnoc---wouldn't that mean that T-dox extended PFS by 100% vs. RFA alone for the tumor sizes involved.


Results
Eighty-seven patients were enrolled in the study; 47%
male and 53% female. The average age was 67 years
(range 37
92). Diagnoses are listed in Table I. The
most common indications for liver-directed therapeutic
ablation were colorectal metastases (38%) and
HCC (26%).
There were 94 ablation procedures for 224 tumors.
Forty-two ablations (45%) were performed open, 7
(7%) laparoscopically, and 45 (48%) percutaneously.
The average tumor size was 3.6 cm(range 0.5
9.0 cm).
Twenty-two lesions were
4 cm. Mean single antenna
ablation volumes were 10.0 ml (range 7.8
14.0 ml),
and clustered antennae ablation volumes were 50.5 ml
(range 21.1
146.5 ml). Outcome variables were measured
with a mean follow-up of 19 months.
Unexpected residual disease was found in five
patients. Expected residual disease was found in three
patients. Local recurrence at ablation sites occurred in
6 (2.7%) tumors and regional recurrence was noted in
37 (43%)